A stunning revelation from the front lines of medicine: Dr. William Makis is reporting what he describes as unprecedented success using ivermectin for two of the most devastating neurological conditions—Parkinson’s and Alzheimer’s disease. What began as an unexpected discovery is now producing results that appear to defy conventional expectations. In Parkinson’s patients, Dr. Makis reports that high-dose ivermectin, in the range of 60–72 mg, has been associated with remarkable improvements. Some patients who were already receiving maximum standard treatments and had become barely mobile reportedly experienced dramatic changes in their movement and symptoms. In one case, a patient who had been unable to play golf for years was reportedly able to return to the course after only a few weeks of treatment. The reported outcomes in Alzheimer’s disease are even more striking. Dr. Makis describes cases in which family members followed a low-dose ivermectin protocol of approximately 12–24 mg for several days and witnessed what they considered extraordinary improvements. Loved ones who had not recognized family members for years reportedly began reconnecting with them, memories appeared to return, and cognitive abilities seemed to improve. In one particularly remarkable case, a patient was reportedly taken off hospice after experiencing a dramatic improvement. The stories are deeply emotional: “My grandma’s back.” Families describe feeling as though they have regained precious time with loved ones they believed they had lost forever—all following treatment with a medication that has been used for decades. Dr. Makis has also challenged the medical establishment, arguing that supportive preclinical research into ivermectin and Alzheimer’s disease has become difficult to find through mainstream search engines. He presents this as evidence of a broader controversy surrounding the investigation of repurposed drugs. Whether these reports ultimately withstand rigorous scientific scrutiny remains to be determined. Nevertheless, if the observations are reproducible, the potential implications are enormous. A safe, accessible, and effective treatment for neurodegenerative diseases would represent a profound medical breakthrough. The question, therefore, is worth asking: If these reports are as compelling as they appear, why aren't the claims being subjected to the highest levels of rigorous clinical research?